// App-Quantinova.ai

7001 : Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.

Researchers

Presenter

  • Nicholas James Short

Principal Investigators

  • Hagop M. Kantarjian

  • Marina Konopleva

  • Nitin Jain

  • Xuelin Huang

  • Farhad Ravandi

  • William G. Wierda

  • Gautam Borthakur

  • Koji Sasaki

  • Ghayas C. Issa

  • Yesid Alvarado

  • Naveen Pemmaraju

  • Guillermo Garcia-Manero

  • Jennifer Thankachan

  • Rebecca Garris

  • Elias Jabbour

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Blinatumomab

  • Ponatinib

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • NCT03263572

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved